Advancing new drug therapies for unmet medical needs

Developing novel drug therapies for unmet medical needs 2018-09-17T09:58:56+00:00

The Dimerix Limited Clinical Trials – ACTION for Diabetic Kidney Disease and ACTION for Focal Segmental Glomerulosclerosis – Are Now Open!

Click Here For More Information

Dimerix Limited is a clinical stage biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB)

Our vision is to positively improve human health by creating safe and effective new treatments for patients with unmet medical needs

Recent news and media

Two Posters Presented at ANZSNASM

Dimerix have presented the following two posters at the ANZSNASM conference. ANZSNASM 2018 ACTION for DKD ANZSNASM 2018 ACTION for FSGS [...]

ASX: Dimerix Executive Team Bolstered Through CEO Appointment

Highlights Experienced biotech and pharmaceuticals professional, Dr Nina Webster to join Dimerix as new Chief Executive Offer and Managing Director, commencing [...]

Click here to view analyst coverage
Click here to view our corporate fact sheet
Click here to view our corporate presentation